Skip to content

Enhanced Spanish Drug Label Study to Promote Patient Understanding and Use

Enhanced Spanish Drug Label Design to Promote Patient Understanding and Use

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01200849
Enrollment
420
Registered
2010-09-14
Start date
2010-10-31
Completion date
2014-01-31
Last updated
2014-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes, Hypertension, Medication Understanding

Brief summary

The overall objective of this study is to test the efficacy of an evidence-based, enhanced Rx container label design to improve Spanish speaking patients' understanding of instructions for use.

Detailed description

The investigators will conduct a randomized controlled trial (N=960) to evaluate the efficacy of the enhanced Rx container label to improve, Spanish speaking, diabetic and/or hypertensive patients' understanding of actual prescribed medicines, compared to a standard label format. Spanish-speaking patients with type II diabetes and/or hypertension at safety-net clinics affiliated with one central-fill pharmacy (Nova Scripts Central - NSC) receive all their prescribed medicines from this location. Recruited diabetic and/or hypertensive subjects in this study will be randomly assigned to either intervention (enhanced Rx container label) or control (standard Rx label). All pill-form, regular dosing schedule medicines, including diabetes and hypertensive (i.e. ACE inhibitor) medicines associated with patients' treatment will be labeled according to study arm by the central-fill pharmacy. Study subjects will be interviewed at the time of dispensing the prescribed medicines at the clinic, again three months later (dispensing of refill), and finally nine months after baseline (dispensing of refill). Pharmacy refill data and medical record information - linked at these clinics - will be collected for exploratory analyses. Patients' ability to read and demonstrate Rx label instructions, including auxiliary warnings, will be the primary outcomes for this aim. Data from the actual use trial will be processed, reviewed, analyzed (in order of hypotheses), and reports prepared during the final months of this last phase of the study. We anticipate several manuscripts to be developed as a result of this project, supported by the diverse key personnel and collaborating faculty enlisted.

Interventions

A prescription drug label that has simplified text, more white space and overall is more patient-friendly.

Sponsors

Agency for Healthcare Research and Quality (AHRQ)
CollaboratorFED
Northwestern University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
30 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Diagnosis of Type II diabetes or hypertension in their medical chart * Spanish speaking * 30 years or older

Exclusion criteria

* Uncorrectable hearing or visual impairment. * Too ill to participate

Design outcomes

Primary

MeasureTime frameDescription
Understanding of prescription medicationBaseline, 3 month follow-up, 9 month follow-upDifference in understanding and comprehension of medication use as compared to control.

Secondary

MeasureTime frame
Change in HbA1c or blood pressure readingsBaseline, 3 month follow-up, 9 month follow-up

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 12, 2026